Adenosine News and Research RSS Feed - Adenosine News and Research

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.
Scientists identify gene that causes hereditary hypertension and brachydactyly type E

Scientists identify gene that causes hereditary hypertension and brachydactyly type E

Individuals with this altered gene have hereditary hypertension (high blood pressure) and at the same time a skeletal malformation called brachydactyly type E, which is characterized by unusually short fingers and toes. The effect on blood pressure is so serious that -- if left untreated -- it most often leads to death before age fifty. [More]
Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. [More]
Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
New model can help predict how humans adapt to high- and low-altitude hypoxia

New model can help predict how humans adapt to high- and low-altitude hypoxia

There are few times in life when one should aim for suboptimal performance, but new research at Rice University suggests scientists who study metabolism and its role in evolution should look for signs of just that. [More]
Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint. [More]
One round of adenosine triphosphate turnover sufficient for SNARE complex disassembly

One round of adenosine triphosphate turnover sufficient for SNARE complex disassembly

In 2013, James E. Rothman, Randy W. Schekman, and Thomas C. Südhof won the Nobel Prize in Physiology or Medicine for their discoveries of molecular machineries for vesicle trafficking, a major transport system in cells for maintaining cellular processes. Vesicle traffic acts as a kind of "home-delivery service" in cells. [More]
Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis. [More]
Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise. [More]
Study shows fatigue pathways are more sensitive in patients with chronic fatigue syndrome

Study shows fatigue pathways are more sensitive in patients with chronic fatigue syndrome

The mechanism that causes high-performance athletes to "feel the burn" turns out to be the culprit in what makes people with chronic fatigue syndrome feel exhausted by the most common daily activities, new University of Florida Health research shows. [More]
Naturally occurring melatonin may help us fall asleep

Naturally occurring melatonin may help us fall asleep

If you walk into your local drug store and ask for a supplement to help you sleep, you might be directed to a bottle labeled "melatonin." The hormone supplement's use as a sleep aid is supported by anecdotal evidence and even some reputable research studies. [More]
New approach could dramatically increase survival rate of cancer patients

New approach could dramatically increase survival rate of cancer patients

Michail Sitkovsky, an immunophysiology expert at Northeastern University, and his research colleagues have made a breakthrough discovery in cancer treatment. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year. [More]
USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for CF101 in the treatment of psoriasis. [More]
Scientists demonstrate the importance of RNA editing in melanoma development

Scientists demonstrate the importance of RNA editing in melanoma development

The importance of RNA editing in melanoma has been demonstrated by scientists at The University of Texas MD Anderson Cancer Center. The study revealed that a lack of RNA editing, a process by which information inside RNA molecules is transformed, leads to tumor growth and progression through manipulation of proteins. [More]
Doctor's Best adds three new sports nutrition powders to its science-based supplement portfolio

Doctor's Best adds three new sports nutrition powders to its science-based supplement portfolio

Doctor's Best has introduced three new sports nutrition powders – Creatine, Branched Chain Amino Acids (BCAA) and L-Arginine - into its science-based supplement portfolio. [More]
Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol. [More]
Reducing A2A adenosine receptor levels prevents memory impairments in Alzheimer's mouse model

Reducing A2A adenosine receptor levels prevents memory impairments in Alzheimer's mouse model

A study by scientists from the Gladstone Institutes shows that decreasing the number of A2A adenosine receptors in a particular type of brain cells called astrocytes improved memory in healthy mice. What's more, reducing receptor levels also prevented memory impairments in a mouse model of Alzheimer's disease. [More]
Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007. [More]
Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101. [More]
Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Advertisement
Advertisement